UiPath (NYSE:PATH) Price Target Raised to $30.00

UiPath (NYSE:PATH) had its price target boosted by equities researchers at Scotiabank from $29.00 to $30.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “sector perform” rating on the healthcare company’s stock. Scotiabank’s price objective suggests a potential upside of 30.07% from the company’s current price.

Several other equities research analysts have also weighed in on the stock. Morgan Stanley increased their price objective on shares of UiPath from $17.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Thursday. TD Cowen raised their price target on shares of UiPath from $25.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday. William Blair started coverage on shares of UiPath in a research note on Tuesday, January 2nd. They issued an “outperform” rating on the stock. Wells Fargo & Company raised their price target on shares of UiPath from $18.00 to $20.00 and gave the company an “equal weight” rating in a research note on Friday, December 1st. Finally, Mizuho raised their price target on shares of UiPath from $18.00 to $22.00 and gave the company a “neutral” rating in a research note on Friday, December 1st. Nine analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $27.13.

UiPath Trading Up 1.4 %

PATH traded up $0.32 on Thursday, hitting $23.07. 9,842,354 shares of the company’s stock were exchanged, compared to its average volume of 10,074,664. The firm has a market cap of $13.06 billion, a PE ratio of -135.46 and a beta of 0.97. UiPath has a twelve month low of $12.38 and a twelve month high of $27.87. The stock has a fifty day moving average of $23.52 and a two-hundred day moving average of $20.70.

Insider Buying and Selling

In related news, Director Rich Wong sold 200,000 shares of the firm’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $23.12, for a total value of $4,624,000.00. Following the completion of the transaction, the director now owns 429,418 shares of the company’s stock, valued at approximately $9,928,144.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other UiPath news, Director Rich Wong sold 200,000 shares of UiPath stock in a transaction on Monday, January 8th. The shares were sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the completion of the sale, the director now owns 429,418 shares of the company’s stock, valued at approximately $9,928,144.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Ashim Gupta sold 70,000 shares of UiPath stock in a transaction on Monday, January 8th. The shares were sold at an average price of $23.02, for a total transaction of $1,611,400.00. Following the sale, the chief financial officer now directly owns 788,148 shares of the company’s stock, valued at approximately $18,143,166.96. The disclosure for this sale can be found here. In the last 90 days, insiders sold 411,000 shares of company stock valued at $9,418,670. Company insiders own 31.03% of the company’s stock.

Institutional Investors Weigh In On UiPath

Institutional investors have recently modified their holdings of the stock. Mark Sheptoff Financial Planning LLC bought a new position in shares of UiPath during the 4th quarter valued at $25,000. HighMark Wealth Management LLC bought a new position in shares of UiPath during the 4th quarter valued at $27,000. Tyler Stone Wealth Management bought a new position in shares of UiPath during the 2nd quarter valued at $28,000. Cypress Capital Management LLC WY bought a new position in UiPath in the 4th quarter worth $29,000. Finally, Fifth Third Bancorp raised its holdings in UiPath by 2,005.3% in the 3rd quarter. Fifth Third Bancorp now owns 2,000 shares of the healthcare company’s stock worth $34,000 after acquiring an additional 1,905 shares during the period. Institutional investors and hedge funds own 59.04% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.